Consistent Trophoblast Cell Surface Antigen 2 Positivity in Tracheobronchial Adenoid Cystic Carcinoma: Expanding Antibody-Drug Conjugate Opportunities in Rare Thoracic Tumor We conducted a ...
Dose-intensive cyclophosphamide, etoposide, cisplatin reinduction for relapsed/refractory aggressive non-Hodgkin lymphoma (r/r-aNHL). The comparison of up-front autologous peripheral stem cell ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved motixafortide combined with filgrastim for mobilization of hematopoietic stem cells into ...
REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last ...
- APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade - - One dosage of APHEXDA plus filgrastim enabled a majority of patients to ...
Leukemia care has entered a new era-one where regenerative medicine and cellular therapy are no longer future concepts, but established tools used in real-world treatment plans. As blood cancers and ...
Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results